CLNT [Cleantech Solutions International,] 10-Q: (Original Filing)

[] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Wind Systems, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER SARBANES-OXLEY ACT OF 2002 I, Fernando, Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Wind Systems, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jianhua Wu Chief Executive Officer Fernando Liu Chief Financial Officer and Principal Accounting Officer EX-32.1 4 v222580_ex32-1.htm]

CLNT [Cleantech Solutions International,] 10-Q:

[] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Wind Systems, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER SARBANES-OXLEY ACT OF 2002 I, Fernando, Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Wind Systems, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jianhua Wu Chief Executive Officer Fernando Liu Chief Financial Officer and Principal Accounting Officer EX-32.1 4 v222580_ex32-1.htm]

CLNT [Cleantech Solutions International,] 10-Q: (Original Filing)

[CHINA WIND SYSTEMS, AND SUBSIDIARIES FORM 10-Q March 31, 2011 TABLE OFNTENTS Page No. PART I. - FINANCIAL INFORMATION Item 1. Financial Statementsnsolidated Balance Sheets of March 31, 2011 (Unaudited) and December 31, 2010 (Audited) 3nsolidated Statements ofome andmprehensiveome for the Three Months Ended March 31, 2011 and 2010 (unaudited)] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1.I have reviewed this quarterly report on Form 10-Q of China Wind Systems,; 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERRBANES-OXLEY ACT OF 2002 I, Fernando, Liu, certify that: 1.I have reviewed this quarterly report on Form 10-Q of China Wind Systems,; 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Jianhua Wu Chief Executive Officer Fernando Liu Chief Financial Officer and Principal Accounting Officer v222580_ex32-1.htm]

CLNT [Cleantech Solutions International,] 10-Q: CHINA WIND SYSTEMS, AND SUBSIDIARIES FORM 10-Q March

[CHINA WIND SYSTEMS, AND SUBSIDIARIES FORM 10-Q March 31, 2011 TABLE OFNTENTS Page No. PART I. - FINANCIAL INFORMATION Item 1. Financial Statementsnsolidated Balance Sheets of March 31, 2011 (Unaudited) and December 31, 2010 (Audited) 3nsolidated Statements ofome andmprehensiveome for the Three Months Ended March 31, 2011 and 2010 (unaudited)] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1.I have reviewed this quarterly report on Form 10-Q of China Wind Systems,; 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERRBANES-OXLEY ACT OF 2002 I, Fernando, Liu, certify that: 1.I have reviewed this quarterly report on Form 10-Q of China Wind Systems,; 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Jianhua Wu Chief Executive Officer Fernando Liu Chief Financial Officer and Principal Accounting Officer v222580_ex32-1.htm]

CLNT [Cleantech Solutions International,] DEF 14A: (Original Filing)

[x o Check the appropriate box: o Preliminary Proxy Statement o x Definitive Proxy Statement o Definitive Additional Materials o China Wind Systems, Inc. N.A. Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction]

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] NT 10-Q: SKYSTAR BIO-PHARMACEUTICAL COMPANY N/A Former name if applicable:

[SKYSTAR BIO-PHARMACEUTICAL COMPANY N/A Former name if applicable: 9595 Wilshire Blvd., Suite 900 Beverly Hills, California 90212 City, state and zip code PART II -- RULES 12b-25(b) AND (c) (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; x (b) The subject annual report, semi-annual report, transition]

By | 2016-03-01T05:24:02+00:00 May 16th, 2011|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

UTSI [UTSTARCOMS] CORRESP: (Original Filing)

[CONFIDENTIAL TREATMENT REQUESTED BY UTSTARCOM, INC. UTSI - 0001 CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED BY [***]. May 16, 2011 VIA EDGAR AND OVERNIGHT DELIVERY Division of Corporation Finance 100 F Street N.E. Mail Stop 3720]

By | 2016-03-01T13:42:20+00:00 May 16th, 2011|Categories: Chinese Stocks, SEC Original, UTSI|Tags: , , , , , |0 Comments

UTSI [UTSTARCOMS] CORRESP: CONFIDENTIAL TREATMENT REQUESTED BY UTSTARCOM, INC. UTSI –

[CONFIDENTIAL TREATMENT REQUESTED BY UTSTARCOM, INC. UTSI - 0001 CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED BY [***]. May 16, 2011 VIA EDGAR AND OVERNIGHT DELIVERY Division of Corporation Finance 100 F Street N.E. Mail Stop 3720]

By | 2016-03-01T13:43:23+00:00 May 16th, 2011|Categories: Chinese Stocks, UTSI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. Reports First Quarter 2011 Results; Revenues Increase 24% to $15.3 Million with Adjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety of pharmaceutical products, today announced]

By | 2016-03-03T12:54:10+00:00 May 16th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Reports First Quarter 2011 Results;

[Biostar Pharmaceuticals, Inc. Reports First Quarter 2011 Results; Revenues Increase 24% to $15.3 Million with Adjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety of pharmaceutical products, today announced]

By | 2016-03-03T12:55:14+00:00 May 16th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar